UNSPSC 51386607: Hydrocortisone/isopropyl alcohol/resorcinol/sulfur

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386607 Hydrocortisone/isopropyl alcohol/resorcinol/sulfur is a Commodity code that in recent state and local procurement activity encompasses naloxone and drug deactivation systems, as well as broader pharmaceutical supply contracts for generic multi-source drugs and over-the-counter products distributed through state and local health systems. The code captures purchases by county health departments, state health and human services agencies, and cooperative purchasing alliances seeking to stock community health initiatives, emergency response programs, and government employee and retiree pharmacy benefits. Issuing bodies span county public health offices (such as Seminole County, Florida), state health agencies (such as the Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (such as the Minnesota Multistate Cooperative Purchasing Alliance). Vendors must comply with FDA requirements, current Good Manufacturing Practices, the Drug Supply Chain Security Act, and federal compliance obligations including E-Verify, drug-free workplace certification, and often federal environmental regulations when FEMA funding is involved. Contracts typically require insurance coverage including workers' compensation, commercial general liability (often $5 million per occurrence), and professional liability; quarterly or regular delivery schedules; and participation in authorized pharmaceutical wholesaler networks or direct-to-manufacturer relationships.

Recent activity spans Florida, Texas, and Minnesota. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline for quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program targeting self-insured employers and state agencies outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, with a March 26, 2026 proposal deadline, seeking generic pharmaceuticals and OTC products for distribution across state and local government facilities in Minnesota and Oregon through authorized wholesalers, with contract effectiveness set for July 1, 2026, and pricing weighted at 75 percent of evaluation criteria.